Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.
Encision's Capital Expenditure for the
three
months ended in Dec. 2023 was $-0.02 Mil. Its Revenue for the
three
months ended in Dec. 2023 was $1.58 Mil.
Hence, Encision's Capex-to-Revenue for the
three
months ended in Dec. 2023 was 0.01.
Encision Capex-to-Revenue Historical Data
The historical data trend for Encision's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Encision's Capex-to-Revenue
For the Medical Instruments & Supplies subindustry, Encision's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Encision's Capex-to-Revenue Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Encision's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where Encision's Capex-to-Revenue falls into.
Encision Capex-to-Revenue Calculation
Encision's Capex-to-Revenue for the fiscal year that ended in Mar. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
Encision Capex-to-Revenue Related Terms
Thank you for viewing the detailed overview of Encision's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Encision Inc is a medical device company. The company develops and markets technology that provides unprecedented outcomes and patient safety in minimally-invasive surgery. The company has established and developed AEM (Active Electrode Monitoring) technology and surgical instruments which provides surgeons with the desired tissue effects of cutting and coagulating tissue in laparoscopic procedures while preventing stray electrosurgical energy that can cause complications and even death. The segments of the company are Product and Service. Product designs develops, manufactures and markets patented surgical instruments. Service performs electrical engineering activities for external entities.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ECIA has been successfully added to your 